Allergan’s Juvederm
This article was originally published in The Gray Sheet
Executive Summary
Anti-aging dermal fillers Juvederm Ultra and Juvedermm Ultra Plus gain expanded labeling approval from FDA for treatment effects lasting up to one year - longer than any other hyaluronic acid-based filler, according to Allergan. Competing treatments include Medicis' Restylane HA-based dermal filler...
You may also be interested in...
Dermal fillers on FDA’s radar
Agency is putting together a "Post Market Issue Action Team" to address complaints about the long-term effects of dermal fillers, Peter Rumm, deputy director of general, restorative and neurological devices at the Office of Device Evaluation, says Sept. 17. Allergan gained expanded labeling in June for treatment effects lasting up to one year with its Juvederm Ultra and Juvederm Ultra Plus dermal fillers (1"The Gray Sheet" July 2, 2007, In Brief). BioForm Medical (Radiesse) and Artes Medical (ArteFill) are among other firms seeking longer-lasting indications
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.